(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.36%) $78.10
(0.23%) $2.21
(-0.29%) $2 317.40
(-0.63%) $27.37
(-0.18%) $986.60
(0.15%) $0.931
(0.40%) $10.94
(0.17%) $0.801
(0.02%) $91.46
5 days till quarter result
(bmo 2024-05-13)
Expected move: +/- 7.56%
2.55% $ 0.540
@ $0.735
Wydano: 14 vas. 2024 @ 21:11
Zwrot: -26.51%
Poprzedni sygnał: vas. 13 - 22:21
Poprzedni sygnał:
Zwrot: 6.03 %
Live Chart Being Loaded With Signals
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation...
Stats | |
---|---|
Dzisiejszy wolumen | 1.66M |
Średni wolumen | 2.36M |
Kapitalizacja rynkowa | 109.96M |
EPS | $0 ( 2024-03-13 ) |
Następna data zysków | ( $-0.220 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.360 |
ATR14 | $0.00100 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-24 | Pooler Amy | Sell | 2 209 | Common Stock |
2024-02-25 | Pooler Amy | Sell | 2 459 | Common Stock |
2024-02-24 | Willoughby Scott B. | Sell | 4 379 | Common Stock |
2024-02-25 | Willoughby Scott B. | Sell | 3 453 | Common Stock |
2024-02-24 | Dubois-stringfellow Nathalie | Sell | 5 474 | Common Stock |
INSIDER POWER |
---|
3.18 |
Last 100 transactions |
Buy: 7 300 210 | Sell: 7 415 564 |
Wolumen Korelacja
Sangamo Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ISNS | 0.898 |
CYRN | 0.889 |
ENNV | 0.884 |
AMTX | 0.884 |
FBIZ | 0.874 |
UK | 0.873 |
ARVN | 0.87 |
CMCT | 0.869 |
CLNE | 0.869 |
FCBC | 0.867 |
10 Najbardziej negatywne korelacje | |
---|---|
BOCH | -0.891 |
ARDX | -0.869 |
CINC | -0.866 |
HEES | -0.86 |
STRL | -0.859 |
OSUR | -0.859 |
ATAK | -0.858 |
BCOR | -0.857 |
LRFC | -0.857 |
STAY | -0.857 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sangamo Therapeutics Inc Korelacja - Waluta/Towar
Sangamo Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $176.23M |
Zysk brutto: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2023 |
Przychody: | $176.23M |
Zysk brutto: | $154.04M (87.41 %) |
EPS: | $-1.480 |
FY | 2022 |
Przychody: | $111.30M |
Zysk brutto: | $99.19M (89.12 %) |
EPS: | $-1.250 |
FY | 2021 |
Przychody: | $110.70M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.230 |
Financial Reports:
No articles found.
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej